Analyst Price Targets — ACHC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 3:52 pm | John Ransom | Raymond James | $25.00 | $21.59 | StreetInsider | Raymond James on Acadia Healthcare (ACHC): '2026 Guide Not as Bad as Feared – Management Change a New Hope' |
| February 26, 2026 11:21 am | Whit Mayo | Leerink Partners | $22.00 | $20.84 | StreetInsider | Acadia Healthcare (ACHC) PT Raised to $22 at Leerink Partners |
| February 23, 2026 11:34 am | Jason Cassorla | Guggenheim | $22.00 | $16.79 | TheFly | Acadia Healthcare price target lowered to $22 from $27 at Guggenheim |
| January 22, 2026 6:04 am | Brian Tanquilut | Jefferies | $15.00 | $14.33 | StreetInsider | Jefferies Downgrades Acadia Healthcare (ACHC) to Hold |
| January 14, 2026 1:19 pm | — | RBC Capital | $17.00 | $12.36 | TheFly | Acadia Healthcare price target lowered to $17 from $19 at RBC Capital |
| December 18, 2025 12:05 pm | — | Mizuho Securities | $17.00 | $14.53 | TheFly | Acadia Healthcare price target lowered to $17 from $22 at Mizuho |
| December 4, 2025 10:49 am | Andrew Mok | Barclays | $14.00 | $14.69 | TheFly | Acadia Healthcare price target lowered to $14 from $17 at Barclays |
| December 3, 2025 1:58 pm | — | RBC Capital | $19.00 | $14.14 | TheFly | Acadia Healthcare price target lowered to $19 from $22 at RBC Capital |
| December 3, 2025 12:58 pm | — | Cantor Fitzgerald | $17.00 | $14.33 | TheFly | Acadia Healthcare price target lowered to $17 from $22 at Cantor Fitzgerald |
| December 3, 2025 12:22 pm | Sarah James | Raymond James | $17.00 | $16.49 | StreetInsider | Acadia Healthcare (ACHC) PT Lowered to $17 at Cantor Fitzgerald |
Latest News for ACHC
Acadia Healthcare (NASDAQ: ACHC) executives used an investor conference appearance to outline operational priorities, discuss recent financial results and guidance, and address topics including payer dynamics, bed ramp-up, and medical malpractice and legal expenses. Company overview and strategic priorities Chief Executive Officer Debbie Osteen opened with a high-level overview of Acadia's footprint and service mix.…
Canyon Capital sold 521,774 shares of Acadia Healthcare in the fourth quarter. The quarter-end position value fell by approximately $12.92 million as a result.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 32,453,225 shares, a growth of 23.1% from the January 29th total of 26,360,014 shares. Currently, 35.9% of the company's shares are short
Acadia Healthcare Company, Inc. (ACHC) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Acadia Healthcare Company, Inc. maintains a Buy rating as new CEO Debbie Osteen focuses on operational stability and disciplined capital allocation amid ongoing industry headwinds. ACHC 2025 revenues reached $3.3bn with adjusted EBITDA of $609m, but a net loss of $1.1bn was driven by a non-cash goodwill impairment. 2026 guidance projects modest revenue growth to $3.37–$3.45bn, adjusted EBITDA of $575–$610m, and EPS…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACHC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.